2025-11-30 - Analysis Report
Okay, let's break down the UNH stock analysis.

**0) Report Overview:**

This report analyzes the performance of UnitedHealth Group Inc. (UNH) relative to the S&P 500 (VOO), examining various financial indicators, recent news, analyst opinions, and earnings data to provide a comprehensive overview for potential investment decisions.

**1) Return Rate Comparison:**

*   **Ticker:** UNH
*   **Company Overview:** UnitedHealth Group Inc. is a diversified health care company offering a wide range of products and services.
*   **UNH Cumulative Return:** -18.51%
*   **VOO (S&P 500) Cumulative Return:** 101.92%
*   **Divergence:** -113.3 (Relative Divergence: 10.4)

**Analysis:**

UNH has significantly underperformed the S&P 500 over the analyzed period. The divergence of -113.3 indicates a substantial difference in cumulative returns. The relative divergence of 10.4 suggests that this underperformance is near the lower end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta | Cap(B) |
|------------|---------|-------|---------|------|--------|
| 2015-2017  | 58.0%   | 66.4% | 30.0%   | 0.1  | 199.7  |
| 2016-2018  | 41.0%   | 70.4% | 26.0%   | 0.1  | 225.7  |
| 2017-2019  | 36.0%   | 73.8% | 14.0%   | 0.2  | 266.3  |
| 2018-2020  | -43.0%  | 81.2% | -67.0%  | 0.5  | 317.7  |
| 2019-2021  | 16.0%   | 81.2% | -30.0%  | 1.5  | 454.9  |
| 2020-2022  | -1.0%   | 81.2% | 0.0%    | 1.5  | 480.3  |
| 2021-2023  | 24.0%   | 80.8% | 23.0%   | 0.4  | 476.9  |
| 2022-2024  | -27.0%  | 78.8% | -47.0%  | 0.3  | 458.2  |
| 2023-2025  | -61.0%  | 79.8% | -127.0% | 1.2  | 298.7  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows a decline, with significant negative growth in recent periods (2018-2020, 2022-2025).
*   **MDD:** The Maximum Drawdown remains high, indicating substantial potential losses.
*   **Alpha:**  Alpha, which measures performance relative to a benchmark, is negative in recent periods, suggesting underperformance.  The -127.0% for 2023-2025 is particularly concerning.
*   **Beta:** Beta has fluctuated, with recent periods showing higher Beta values (especially 2019-2022), indicating increased volatility and correlation with the market.
*   **Cap(B):** Market capitalization has decreased recently, potentially due to the declining stock price.

**2) Recent Stock Price Fluctuations:**

*   **Close:** 329.77
*   **Last Market:** Price: 329.77, Previous Close: 329.71, Change: 0.02
*   **5-day SMA:** 324.956
*   **20-day SMA:** 324.902
*   **60-day SMA:** 342.618

**Analysis:**

The stock price is currently slightly above the 5-day and 20-day Simple Moving Averages (SMAs), but significantly below the 60-day SMA. This suggests a possible short-term upward trend, but the price is still struggling to recover to its medium-term levels.

**3) RSI, PPO, and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 53.83
*   **PPO:** 0.42
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (264 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** 2.3 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -153.5

**Analysis:**

*   The MRI suggests that the current market conditions are considered relatively safe for investment (high investment recommended).
*   The RSI of 53.83 indicates that the stock is neither overbought nor oversold.
*   The PPO of 0.42 is near zero, implying minimal momentum.
*   The hybrid signal suggests a strong buy recommendation based on the MRI.
*   The recent positive change in relative divergence indicates a short-term upward trend.
*   **The most alarming metric is the Expected Return of -153.5%, indicating a very poor outlook for long-term investment compared to the S&P 500.** This contradicts the MRI and Hybrid Signal, highlighting a major concern.

**4) Recent News & Significant Events:**

*   **Major Theme:** The recent news headlines predominantly discuss a significant drop in UnitedHealth's stock price, attributing it to factors like the MCR (Medical Care Ratio) crisis and DOJ investigation. The news suggests potential valuation opportunities but also warns of cost fears.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (~2.00)
*   **Target Price (avg/high/low):** 386.72 / 440.00 / 198.00

**Analysis:**

Analysts, on average, maintain a "Buy" rating with a target price significantly higher than the current price. However, the wide range between the high and low target prices (198.00 to 440.00) indicates uncertainty among analysts.  Given the recent negative news and poor performance, the "Buy" consensus is questionable and warrants further scrutiny.

**5) Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-10-28 | 2.59 | 113.16 B$    |
| 2025-08-11 | 3.76 | 111.62 B$    |
| 2025-05-07 | 6.9  | 109.58 B$    |
| 2024-11-04 | 6.56 | 100.82 B$    |
| 2025-10-28 | 6.56 | 100.82 B$    |

**Analysis:**

*   Revenue shows an upward trend.
*   EPS appears to have significant fluctuation.

**6) Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue      | Profit Margin |
|--------------|--------------|---------------|
| 2025-09-30   | $113.16B     | 18.24%        |
| 2025-06-30   | $111.62B     | 17.93%        |
| 2025-03-31   | $109.58B     | 21.70%        |
| 2024-12-31   | $100.81B     | 21.14%        |
| 2024-09-30   | $100.82B     | 22.84%        |

Capital and Profitability:

| Quarter      | Equity      | ROE     |
|--------------|-------------|---------|
| 2025-09-30   | $95.79B    | 2.45%   |
| 2025-06-30   | $94.72B    | 3.60%   |
| 2025-03-31   | $95.04B    | 6.62%   |
| 2024-12-31   | $92.66B    | 5.98%   |
| 2024-09-30   | $94.53B    | 6.41%   |

**Analysis:**

*   Revenue is increasing, showing growth in the company's top line.
*   Profit Margins have fluctuated, with a slight decrease in recent quarters.
*   Equity has remained relatively stable.
*   ROE (Return on Equity) has decreased in recent quarters, potentially due to the decrease in profit margin and the stock price drop.

**7) Comprehensive Analysis (Summary):**

*   **Underperformance:** UNH has significantly underperformed the S&P 500, and recent Alpha values are concerning.
*   **Price Action:** The stock price is below its 60-day SMA, indicating a potential struggle to recover in the medium term.
*   **Conflicting Signals:** The MRI suggests a safe investment environment, and the Hybrid Signal gives a strong buy signal. However, the *extremely negative* Expected Return (-153.5%) strongly contradicts this, as it indicates substantial underperformance compared to the S&P 500 for long-term investors.
*   **Negative News:** Recent news highlights significant stock price declines due to MCR concerns and a DOJ investigation.
*   **Analyst Disagreement:** While analysts maintain a "Buy" consensus, the wide range of target prices suggests uncertainty. This consensus seems questionable in light of recent negative news and financial performance.
*   **Financials:** Revenue is increasing, but profit margins and ROE have decreased.

**Overall Conclusion:**

The report presents a mixed picture for UNH. While the MRI and short-term technical indicators might suggest a buying opportunity, the significant underperformance compared to the S&P 500, negative news, decreasing profitability, and, crucially, the *extremely negative* expected return, warrant extreme caution. The Analyst's "Buy" consensus is also suspicious.

**Recommendation:**

Based on this analysis, **investing in UNH is high risk.** Further investigation is needed to understand the reasons behind the discrepancy between the MRI and Expected Return. The MCR crisis and DOJ investigation present substantial uncertainty. It's advisable to avoid investing in UNH until a clearer picture emerges and the negative factors are addressed.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.